FCT
VRTX icon

Family Capital Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Family Capital Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-480
Closed -$34K – 91
2014
Q1 		$34K Hold
480
– – 0.02% 81
2013
Q4 		$36K Hold
480
– – 0.02% 80
2013
Q3 		$36K Hold
480
– – 0.02% 86
2013
Q2 		$38K Buy
+480
New +$35.3K 0.02% 88

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Family Capital Trust's VRTX Position: Q2 2014 in Review

Family Capital Trust sold out of Vertex Pharmaceuticals (VRTX) in Q2 2014, closing a stake of 480 shares — an estimated $34K sold.

Family Capital Trust first reported a position in VRTX in Q2 2013 and held it in 4 quarters. The position peaked at $38K in Q2 2013. 411 funds tracked by Wall St. Rank hold VRTX as of Q2 2014.

  • Family Capital Trust reported no remaining Vertex Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Family Capital Trust sold 480 Vertex Pharmaceuticals shares in Q2 2014, an estimated $34K.
  • Family Capital Trust first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Family Capital Trust's Vertex Pharmaceuticals position peaked at $38K in Q2 2013.
  • 411 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2014.

Based on Family Capital Trust's 13F filing for Q2 2014, filed 5 Aug 2014.